Cited by 42Cancer Genomics and DiagnosticsSarcoma Diagnosis and TreatmentGenomic variations and chromosomal abnormalities

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas

Open access

Abstract

Most circulating tumor DNA (ctDNA) assays are designed to detect recurrent mutations. Pediatric sarcomas share few recurrent mutations but rather are characterized by translocations and copy-number changes. We applied Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) for detection of translocations found in the most common pediatric sarcomas. We also applied ichorCNA to the combined off-target reads from our hybrid capture to simultaneously detect copy-number alterations (CNA). We analyzed 64 prospectively collected plasma samples from 17 patients with pediatric sarcoma. Translocations were detected in the pretreatment plasma of 13 patients and were confirmed by tumor sequencing in 12 patients. Two of these patients had evidence of complex chromosomal rearrangements in their ctDNA. We also detected copy-number changes in the pretreatment plasma of 7 patients. We found that ctDNA levels correlated with metastatic status and clinical response. Furthermore, we detected rising ctDNA levels before relapse was clinically apparent, demonstrating the high sensitivity of our assay. This assay can be utilized for simultaneous detection of translocations and CNAs in the plasma of patients with pediatric sarcoma. While we describe our experience in pediatric sarcomas, this approach can be applied to other tumors that are driven by structural variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-20-0987

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Broad plasma panels, CNA-based WGS, methylation-based assays, cfRNA approaches, and CTC-based strategies remain more exploratory or proof-of-concept in most sarcoma subtypes, particularly when applied to low-volume MRD or routine surveillance settings.

    “In contrast, broad plasma panels, CNA-based WGS, methylation-based assays, cfRNA approaches, and CTC-based strategies remain more exploratory or proof-of-concept in most sarcoma subtypes, particularly when applied to low-volume MRD or routine surveillance settings [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., Behroozfard, I. H., Wittber, F. M., Hazard, F. K., Cho, S.-J., Daldrup-Link, H. E., Vo, K. T., Rangaswami, A., Pribnow, A., Spunt, S. L., Lacayo, N. J., Diehn, M., Alizadeh, A. A., & Sweet-Cordero, E. A.
Affiliations
  • University of California, San Francisco (US)
  • Stanford Medicine (US)
  • 1Division of Hematology/Oncology, Department of Pediatrics, University of California San Francisco, San Fransisco, California.
Venue
Molecular Cancer Therapeutics
Published
2021-08-05
Volume
20
Issue
10
Pages
2016-2025
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3187847571
Cited by
42
References
46
Citations by year
2026: 7 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 5
FWCI
2.68
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • St. Baldrick's Research Fellowship Grant
  • Alex's Lemonade Stand Foundation
  • Frank A. Campini Foundation
  • Doris Duke Clinical Research Mentorship Award
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD081123A)
  • Child Health Research Institute
  • Children's Oncology Group Solid Malignancy-Integrated Translational Science Center
  • Lucile Packard Children's Hospital
  • Helen Diller Family Comprehensive Cancer Center
  • NIH S10 Shared Instrumentation Grant (S10OD018220)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords
circulating tumor DNA, pediatric sarcoma, translocation, copy number alterations, liquid biopsy, CAPP-Seq, ichorCNA, structural variants, complex chromosomal rearrangements, plasma biomarkers, metastasis, relapse detection, hybrid capture sequencing
MeSH terms
Circulating Tumor DNA, Child, DNA, Neoplasm, Follow-Up Studies, Humans, Longitudinal Studies, Mutation, Neoplasm Recurrence, Local, Prognosis, Prospective Studies, Sarcoma, Translocation, Genetic, Biomarkers, Tumor, DNA Copy Number Variations, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review